PLUS THERAPEUTICS Inc. (PSTV)

Name: PLUS THERAPEUTICS Inc. (PSTV) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: PLUS THERAPEUTICS Inc. (PSTV)

Stock Card

$3.84

$0.07 (1.80%)

As on 07-Aug-2026 09:30EDT

Market cap

$27 Mln

Revenue (TTM)

$4 Mln

P/E Ratio

0.2

P/B Ratio

4.3

Div. Yield

0 %

PLUS THERAPEUTICS (PSTV) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 3.77 High: 3.96

52 Week Range

Low: 2.90 High: 23.43

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-5.2 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

29.1
Debt to Equity

0
Book Value

$--
EPS

$-4.2
Face value

--
Shares outstanding

6,883,897

10 Years Aggregate

CFO

$-150.88 Mln

EBITDA

$-153.19 Mln

Net Profit

$-184.05 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
PLUS THERAPEUTICS (PSTV)	-70.0	-5.2	-36.0	-79.8	-59.7	-65.0	-68.4
BSE Sensex^*	-9.1	-1.2	2.9	-3.6	5.7	6.2	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 07-Aug-2026 | *As on 31-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
PLUS THERAPEUTICS (PSTV)	-55.5	-34.1	-63.2	-69.5	-48.0	-15.8	-83.4
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
PLUS THERAPEUTICS (PSTV)	3.8	26.6	4.2	-26.1	-539.7	-551.6	0.2	4.3
Arrowhead Pharmaceuticals (ARWR)	84.9	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Ascendis Pharma A/S - ADR	247.9	16,261.1	1,054.4	755.9	5.7	--	19	9.8
Cytokinetics Inc (CYTK)	72.1	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	54.5	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	105.4	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	351.5	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Madrigal Pharmaceuticals (MDGL)	533.8	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	600.7	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3
Praxis Precision MedicinesÂ Inc (PRAX)	344.8	9,625.4	0.0	-339.1	--	-30.6	--	7.6

Shareholding Pattern

View Details

About PLUS THERAPEUTICS (PSTV)

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented... radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas. Read more

President, CEO & Director

Dr. Marc H. Hedrick M.B.A., M.D.
President, CEO & Director

Dr. Marc H. Hedrick M.B.A., M.D.
Headquarters

Houston, TX
Website

https://plustherapeutics.com

FAQs for PLUS THERAPEUTICS (PSTV)

What is the current share price of PLUS THERAPEUTICS Inc (PSTV) Today?

The share price of PLUS THERAPEUTICS Inc (PSTV) is $3.84 (NASDAQ) as of 07-Aug-2026 09:30 EDT. PLUS THERAPEUTICS Inc (PSTV) has given a return of -59.67% in the last 3 years.

What is the current PB & PE ratio of PLUS THERAPEUTICS Inc (PSTV)?

The P/E ratio of PLUS THERAPEUTICS Inc (PSTV) is 0.18 times as on 07-Aug-2026.
The P/B ratio of PLUS THERAPEUTICS Inc (PSTV) is 4.31 times as on 07-Aug-2026, a 17 discount to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-0.07	0.40
2024	-0.52	-0.76
2023	-0.59	-5.84
2022	-0.03	0.09
2021	-0.06	0.08

What is the 52 Week High and Low of PLUS THERAPEUTICS Inc (PSTV)?

The 52-week high and low of PLUS THERAPEUTICS Inc (PSTV) are Rs 23.43 and Rs 2.90 as of 31-Aug-2026.

What is the market cap of PLUS THERAPEUTICS Inc (PSTV)?

PLUS THERAPEUTICS Inc (PSTV) has a market capitalisation of $ 27 Mln as on 07-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in PLUS THERAPEUTICS Inc (PSTV)?

Before investing in PLUS THERAPEUTICS Inc (PSTV), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.